Division of Digestive and Liver Diseases, Department of Internal Medicine.
Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX.
Liver Transpl. 2018 Oct;24(10):1357-1362. doi: 10.1002/lt.25285.
Liver transplantation (LT) has a demonstrated survival benefit in select patients with severe acute alcoholic hepatitis (SAH) who do not respond to steroids, but prior studies suggest low adoption among US LT centers. Our study explored current perceptions and practice patterns of LT for SAH in the United States. We administered a Web-based survey to medical directors of US LT centers between May and October of 2017 to characterize practice patterns and perceptions of LT for SAH. We obtained responses from 45 (41.3%) of 109 surveyed centers, representing all 11 (100%) United Network for Organ Sharing regions. Half (n = 23; 51.1%) reported performing at least 1 LT for SAH, although most (n = 19; 82.6%) of those had performed ≤5 LTs for that indication. Centers expressed near consensus for selection criteria, requiring strong social support (100%), no prior presentations with SAH (91.3%), absence of a severe coexisting psychiatric disorder (91.3%), and official psychosocial evaluation (87.0%). Reported posttransplant survival of SAH patients was excellent, with 17 (73.9%) centers reporting 1-year posttransplant survival exceeding 90%. Among centers that had not performed LT for SAH, the most commonly cited reason was perceived high risk of alcohol relapse. In conclusion, our data demonstrate that LT is increasingly adopted as a therapeutic intervention for patients with SAH and that careful selection allows for excellent 1-year posttransplant survival. Despite this, nearly half of US centers do not perform LT for this indication due to perceived high risk of alcohol relapse. Our data support the use of LT for well-selected patients with SAH.
肝移植(LT)已被证明可使部分对类固醇治疗无反应的严重急性酒精性肝炎(SAH)患者受益,但先前的研究表明,美国 LT 中心的采用率较低。我们的研究探讨了目前美国 LT 治疗 SAH 的看法和实践模式。我们于 2017 年 5 月至 10 月期间向美国 LT 中心的医学主任进行了一项基于网络的调查,以描述 LT 治疗 SAH 的实践模式和看法。我们从 109 家调查中心中获得了 45 家(41.3%)的回复,这些中心代表了所有 11 个(100%)联合器官共享网络地区。尽管大多数(n = 19;82.6%)中心仅进行过≤5 例用于该适应症的 LT,但有一半(n = 23;51.1%)的中心报告至少进行过 1 例 LT 治疗 SAH。中心对选择标准的表达几乎达成共识,需要强烈的社会支持(100%)、无既往 SAH 发作(91.3%)、无严重并存的精神疾病(91.3%)和正式的社会心理评估(87.0%)。SAH 患者的报告移植后存活率非常高,有 17 家(73.9%)中心报告 1 年移植后存活率超过 90%。在未进行 LT 治疗的中心中,最常提到的原因是认为酒精复发风险高。总之,我们的数据表明,LT 作为治疗 SAH 患者的治疗干预措施越来越被采用,并且仔细的选择可以实现极好的 1 年移植后存活率。尽管如此,近一半的美国中心由于认为酒精复发风险高而不进行 LT 治疗。我们的数据支持对符合条件的 SAH 患者使用 LT。